Download PDF
1 / Pages

Other users also viewed these articles

Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up Ester Badia Aranda; Cristina Fernández Marcos; Aida Puebla Maestu; Visitación Gozalo Marín; Raquel Vinuesa Campo; Sara Calvo Simal; Judith Gómez Camarero;
Gastroenterol Hepatol. 2022;45:767-79
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy Joan Martínez-Campreciós; Mar Riveiro-Barciela; Raquel Muñoz-Gómez; María-Carlota Londoño; Mercé Roget; Miguel Ángel Serra; Desamparados Escudero-García; Laura Purchades; Manuel Rodríguez; Juan E. Losa-García; María L. Gutiérrez; Isabel Carmona; Javier García-Samaniego; Luís Morano; Ignacio Martín-Granizo; Marta Montero-Alonso; Martín Prieto; Manuel Delgado; Natalia Ramos; María A. Azancot; Francisco Rodríguez-Frías; Maria Buti;
Gastroenterol Hepatol. 2023;46:594-602
Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review Luis Gutiérrez-Rojas; Jesús José de la Gándara Martín; Luisa García Buey; Juan I. Uriz Otano; Álvaro Mena; Carlos Roncero;
Gastroenterol Hepatol. 2023;46:382-96